LENZ Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:
TD Cowen 46th Annual Health Care Conference
Date: March 2, 2026
Location: Boston, MA
Format: Fireside chat at 9:50am ET (live audio ) and 1x1 investor meetings
Leerink Partners 2026 Global Healthcare Conference
Date: March 10, 2026
Location: Miami, FL
Format: Fireside chat at 10:00am ET (live audio ) and 1x1 investor meetings
Live audio webcasts will also be available on the LENZ Therapeutics website at in the Investors & Media section. A replay of the webcasts will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit and .
Contacts:
Dan Chevallard
LENZ Therapeutics
